Aspira Women’s Health is Dedicated to Transforming Women’s Gynecologic Health
Starting with Ovarian Cancer

The Ovarian Cancer story has to change, Aspira is passionately dedicated to making a difference.

Aspira Women's Health’s wholly owned subsidiary, Aspira Labs, is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory committed to solving women's health issues for all ethnicities, stages, and ages. Our data-driven approach delivers solutions that help women take control of their gynecologic health and empowers providers to deliver optimal care. We are using our decades of experience in ovarian cancer risk assessment to develop a cutting-edge portfolio of pelvic mass products.

Learn About Our Research


  • Ova1® is great in that it can help to avoid second procedures on patients and second operations which can be associated with higher morbidity.

    - Jonathan Black MD, MPH
  • Ova1Plus® has added to our armamentarium as physicians by decreasing the false positive rate up to 50%

    - Howard C. Mandel MD, FACOG

Our Products

  • OvaWatch℠ is intended to assist in assessing the risk of ovarian cancer when a healthcare provider’s initial clinical assessment of the adnexal mass is either indeterminant or benign.

    Learn More
  • Part of the OvaSuite℠ portfolio of blood tests, Ova1Plus® is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

    Learn More